Hyperforin dicyclohexylammonium salt (Hyperforin DCHA)
A stable salt of hyperforin, which is the primary active constituent responsible for the antidepressant and anxiolytic properties of St. John′s Wort
Aphios manufactures a hyperforin-rich extract [Castor, US Patent] from the flowers and buds of Hypericum perforatum (St. John's Wort) utilizing its patented SuperFluids™ CXP technology. Hyperforin is purified and stabilized by the formation of the dicyclohexylammonium salt.
Hyperforin DCHA is a stable salt of hyperforin, which is the primary active constituent responsible for the antidepressant and anxiolytic properties of St. John's Wort extracts.
Hyperforin acts as a reuptake inhibitor of serotonin and other monoamines including norepinephrine, dopamine, and GABA and glutamate by activating the transient receptor potential ion channel TRPC6. It also is an activator of the pregnane X receptor (PXR), which serves as a key regulator of CYP3A4 transcription, a member of the cytochrome (CYP) P450 enzyme system. Recent studies have found other neurological effects, effects on inflammation, as well as antibacterial, antitumoral and antiangiogenic effects.
Beerhues L. (2006). Hyperforin. Phytochemistry. 67, 2201-2207.
Cantoni L, Rozio M, Mangolini A, Hauri L and Caccia S. (2003). Hyperforin Contributes to the Hepatic CYP3A-Inducing Effect of Hypericum perforatum Extract in the Mouse. Toxicological Sciences. 75, 25-30.
Cervo L, Rozio M, Ekalle-Soppo C, Guiso G, Morazzoni P and Caccia S. (2002). Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology, 164, 423-428.
Linde K, Ramirez G, Murlow CD, Pauls A, Weidenhammer W and Melchart D. (1996). St John's wort for depression—an overview and meta-analysis of randomized clinical trials. BMJ. Aug 3; 313(7052):253-258.
Woelk H. (2000). Comparison of St John's wort and imipramine for treating depression: randomized controlled trials. BMJ. 321, 536-539.